Vascular Smooth Muscle Cells in CADASIL

Vascular Smooth Muscle Cells in CADASIL

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Vascular Smooth Muscle Cells in CADASIL</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Chromosome 19p13.12</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>NOTCH3 receptor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>VSMCs, pericytes</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Cell differentiation, survival</td>
</tr>
<tr>
<td class="label">Mutations</td>
<td>Cysteine-altering in EGF-like domains</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Location</td>
<td>VSMC basal membrane</td>
</tr>
<tr>
<td class="label">Composition</td>
<td>NOTCH3 ectodomain, TIMP3, vitronectin</td>
</tr>
<tr>
<td class="label">Detection</td>
<td>Electron microscopy (gold standard)</td>
</tr>
<tr>
<td class="label">Specificity</td>
<td>Pathognomonic for CADASIL</td>
</tr>
<tr>
<td class="label">Vessel Type</td>
<td>Pathological Change</td>
</tr>
<tr>
<td class="label">Small arteries</td>
<td>Wall thickening, VSMC loss</td>
</tr>
<tr>
<td class="label">Arterioles</td>
<td>Fibrosis, hyalinosis</td>
</tr>
<tr>
<td class="label">Capillaries</td>
<td>Pericyte involvement</td>
</tr>
<tr>
<td class="label">Veins</td>
<td>Generally spared</td>
<

Vascular Smooth Muscle Cells in CADASIL

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Vascular Smooth Muscle Cells in CADASIL</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Chromosome 19p13.12</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>NOTCH3 receptor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>VSMCs, pericytes</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Cell differentiation, survival</td>
</tr>
<tr>
<td class="label">Mutations</td>
<td>Cysteine-altering in EGF-like domains</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Location</td>
<td>VSMC basal membrane</td>
</tr>
<tr>
<td class="label">Composition</td>
<td>NOTCH3 ectodomain, TIMP3, vitronectin</td>
</tr>
<tr>
<td class="label">Detection</td>
<td>Electron microscopy (gold standard)</td>
</tr>
<tr>
<td class="label">Specificity</td>
<td>Pathognomonic for CADASIL</td>
</tr>
<tr>
<td class="label">Vessel Type</td>
<td>Pathological Change</td>
</tr>
<tr>
<td class="label">Small arteries</td>
<td>Wall thickening, VSMC loss</td>
</tr>
<tr>
<td class="label">Arterioles</td>
<td>Fibrosis, hyalinosis</td>
</tr>
<tr>
<td class="label">Capillaries</td>
<td>Pericyte involvement</td>
</tr>
<tr>
<td class="label">Veins</td>
<td>Generally spared</td>
</tr>
<tr>
<td class="label">Region</td>
<td>CBF Change</td>
</tr>
<tr>
<td class="label">White matter</td>
<td>↓30-50%</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>↓20-40%</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>↓10-30%</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Age of Onset</td>
</tr>
<tr>
<td class="label">Migraine with aura</td>
<td>20-40 years</td>
</tr>
<tr>
<td class="label">TIA/stroke</td>
<td>40-60 years</td>
</tr>
<tr>
<td class="label">Cognitive decline</td>
<td>40-70 years</td>
</tr>
<tr>
<td class="label">Psychiatric symptoms</td>
<td>30-50 years</td>
</tr>
<tr>
<td class="label">Gait disturbance</td>
<td>50-70 years</td>
</tr>
<tr>
<td class="label">Normal Function</td>
<td>CADASIL Effect</td>
</tr>
<tr>
<td class="label">VSMC differentiation</td>
<td>Impaired</td>
</tr>
<tr>
<td class="label">Cell survival signaling</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Smooth muscle gene expression</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">Calcium handling</td>
<td>Abnormal</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>↑ ROS markers</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>↑ Cytokines</td>
</tr>
<tr>
<td class="label">BBB breakdown</td>
<td>Albumin leakage</td>
</tr>
<tr>
<td class="label">Impaired autophagy</td>
<td>LC3 accumulation</td>
</tr>
<tr>
<td class="label">Shared Feature</td>
<td>CADASIL</td>
</tr>
<tr>
<td class="label">VSMC loss</td>
<td>Prominent</td>
</tr>
<tr>
<td class="label">White matter injury</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">BBB dysfunction</td>
<td>Early</td>
</tr>
<tr>
<td class="label">Cognitive pattern</td>
<td>Subcortical</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">CADASIL</td>
<td>NOTCH3</td>
</tr>
<tr>
<td class="label">CARASIL</td>
<td>HTRA1</td>
</tr>
<tr>
<td class="label">RVCL</td>
<td>TREX1</td>
</tr>
<tr>
<td class="label">Fabry disease</td>
<td>GLA</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Sensitivity</td>
</tr>
<tr>
<td class="label">GOM on EM</td>
<td>45-90%</td>
</tr>
<tr>
<td class="label">NOTCH3 IHC</td>
<td>85-95%</td>
</tr>
<tr>
<td class="label">Combined</td>
<td>95%+</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Neurofilament light (NfL)</td>
<td>Disease activity</td>
</tr>
<tr>
<td class="label">MMP-9</td>
<td>Vessel wall turnover</td>
</tr>
<tr>
<td class="label">TIMP3</td>
<td>GOM-related</td>
</tr>
<tr>
<td class="label">Cystatin C</td>
<td>Renal + vascular</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Antiplatelet therapy</td>
<td>Stroke prevention</td>
</tr>
<tr>
<td class="label">Blood pressure control</td>
<td>Vascular protection</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Mixed evidence</td>
</tr>
<tr>
<td class="label">Smoking cessation</td>
<td>Risk reduction</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NOTCH3 monoclonal antibodies</td>
<td>Clear aggregates</td>
</tr>
<tr>
<td class="label">Autophagy enhancers</td>
<td>Protein clearance</td>
</tr>
<tr>
<td class="label">Anti-aggregation compounds</td>
<td>Prevent GOM</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Correct mutation</td>
</tr>
<tr>
<td class="label">Assessment</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Neurological exam</td>
<td>Annual</td>
</tr>
<tr>
<td class="label">MRI brain</td>
<td>Every 2-3 years</td>
</tr>
<tr>
<td class="label">Cognitive testing</td>
<td>Annual</td>
</tr>
<tr>
<td class="label">Blood pressure</td>
<td>Regular</td>
</tr>
<tr>
<td class="label">Depression screening</td>
<td>Annual</td>
</tr>
</table>

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary small vessel disease caused by NOTCH3 mutations affecting vascular smooth muscle cells (VSMCs) in cerebral arteries and arterioles. VSMC degeneration is the pathological hallmark of CADASIL, leading to vessel wall thickening, luminal narrowing, reduced cerebral blood flow, and ischemic brain injury. Understanding VSMC pathology in CADASIL provides insights into vascular contributions to neurodegeneration and potential therapeutic targets.

CADASIL Genetics and Pathophysiology

NOTCH3 Gene

Mutation Mechanism

CADASIL-causing mutations are stereotypic:

• Cysteine gain/loss: Odd number of cysteines in EGF-like domain
• Hotspots: Exons 2-24 encoding EGF-like repeats
• Effect: Abnormal protein folding and aggregation
• Inheritance: Autosomal dominant with variable penetrance

NOTCH3 Structure

• Extracellular domain: 34 EGF-like repeats
• Transmembrane domain: Single-pass
• Intracellular domain: Transcriptional activation
• Ligands: Jagged1/2, Delta-like 1/3/4

Vascular Smooth Muscle Cell Pathology

Granular Osmiophilic Material (GOM)

The characteristic pathological finding in CADASIL:

GOM Formation Process

VSMC Degeneration

Progressive VSMC loss through:

Vascular Pathology

Small Vessel Changes

Vessel Wall Changes

• Intimal hyperplasia: Fibrous intimal thickening
• Media degeneration: VSMC loss, collagen deposition
• Adventitial fibrosis: Perivascular collagen
• Luminal narrowing: 30-70% reduction common

Cerebral Blood Flow Reduction

Clinical Manifestations

Core Features

MRI Findings

Characteristic neuroimaging features:

• White matter hyperintensities: Anterior temporal, external capsule
• Lacunar infarcts: Basal ganglia, thalamus, brainstem
• Cerebral microbleeds: 10-30% of patients
• Brain atrophy: Frontal, temporal predominance

Disease Progression

Molecular Mechanisms

NOTCH3 Signaling Disruption

Protein Aggregation Toxicity

Secondary Pathogenic Mechanisms

Relationship to Other Neurodegenerative Disorders

Vascular Contributions to Cognitive Impairment

CADASIL provides a model for understanding vascular contributions to neurodegeneration:

Overlap with Alzheimer Pathology

• Amyloid deposition: Increased in CADASIL vessels
• Tau pathology: Secondary to ischemic injury
• ApoE4 association: May accelerate decline
• Mixed dementia: CADASIL + AD pathology common

Comparison with Other Vasculopathies

Diagnostic Approaches

Genetic Testing

• NOTCH3 sequencing: Standard diagnostic test
• Targeted exons: Exons 2-24 cover 95%+ mutations
• Variants of unknown significance: Clinical correlation needed

Skin Biopsy

Biomarkers

Therapeutic Approaches

Current Management

Disease-Modifying Strategies

Symptomatic Treatment

Research Directions

Clinical Trials

• ESCAPE-CADASIL: Evaluating strategies for vascular protection
• CADASIL-TCH: Tadalafil for cerebral blood flow
• Anti-aggregation: Targeting GOM formation

Emerging Therapeutic Targets

Biomarker Development

• CSF biomarkers: NfL, tau, amyloid ratios
• Blood biomarkers: NfL, GFAP, inflammatory markers
• Imaging biomarkers: MRI, PET, ultrasound
• Functional biomarkers: CBF, vascular reactivity

Clinical Management Algorithm

Monitoring Recommendations

Genetic Counseling

• Inheritance risk: 50% transmission to offspring
• Variable expressivity: Severity unpredictable
• Presymptomatic testing: Available with counseling
• Family screening: Important for at-risk relatives
• [Neurons — Major brain cell type](/cell-types/neurons)](/entities/neurons)
• [Glia — Support cells in the brain](/genes/th)
• [Alzheimer's Disease — Related neurodegenerative disease](/genes/rel)
• [Parkinson's Disease — Related neurodegenerative disease](/genes/ar)

External Links

• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature